Module 1: Risk stratification of patients with biochemical recurrence after primary therapy for early hormone-sensitive prostate cancer
Primary Audience:
This activity is intended to meet the educational needs of urologists, medical oncologists and radiation oncologists involved in the care of patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC).
This module will cover risk stratification in patients who have had primary therapy and subsequent biochemical recurrence, with a focus on high- and very high-risk patients.
Catherine Handy Marshall, MD, MPH
Assistant Professor of Oncology
Internal Medicine, Oncology
Johns Hopkins School of Medicine
Baltimore, MD
Dr. Catherine Marshall is an Assistant Professor in the Department of Oncology at the Johns Hopkins University School of Medicine. Her areas of clinical expertise include internal medicine and oncology.
She received her M.D. and M.P.H. from Johns Hopkins, where she also completed her residency and an oncology fellowship.
1.
Develop the ability to appropriately risk-stratify patients with biochemical recurrence after primary therapy for nmHSPC based on existing data and guidelines.
